25 completed, 7 recruiting, 5 active not recruiting, 4 terminated. 46 Phase 3, 7 Phase 2.
Follow Mitochondrial Diseases: new trials by email Literature Review of Mitochondrial Diseases trials Research Report on Mitochondrial Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Modafinil to Treat Fatigue in People With Mitochondrial Disease. Modafinil (M), Placebo - Mitochondrial Disease | Phase 3 | Not yet recruiting | Kenneth Myers, MD | 15 | 2026-12-01 | 2026-10-26 |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia Nomlabofusp, Placebo - Friedreich Ataxia, Friedreich's Ataxia | Phase 3 | Recruiting | Larimar Therapeutics, Inc. | 150 | 2026-10-26 | 2026-10-09 |
| Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA) Vatiquinone - Friedreich's Ataxia | Phase 3 | Not yet recruiting | PTC Therapeutics | 120 | 2026-08-15 | 2026-08-14 |
| KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases Sonlicromanol, Placebo - Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD) | Phase 3 | Recruiting | Khondrion BV | 220 | 2026-04-14 | 2026-10-14 |
| A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia Omaveloxolone, Placebo - Friedreich Ataxia | Phase 3 | Active not recruiting | Biogen | 255 | 2025-06-09 | 2026-10-02 |
| Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) sepofarsen, Placebo IVT - Leber Congenital Amaurosis 10, Blindness | Phase 3 | Recruiting | Laboratoires Thea | 32 | 2025-06-04 | 2026-10-21 |
| A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation rAAV2-ND4, Sham (No Treatment) - Leber Hereditary Optic Neuropathy (LHON) | Phase 3 | Active not recruiting | Wuhan Neurophth Biotechnology Limited Company | 95 | 2024-09-19 | 2026-02-12 |
| Coenzyme Q10 for Gulf War Illness: A Replication Study PharmaNord Bio-Quinone Active CoQ10 Gold 100mg, PharmaNord Placebo - Gulf War Syndrome, Persian Gulf Syndrome | Phase 3 | Recruiting | University of California, San Diego | 192 | 2024-09-13 | 2026-05-01 |
| CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease CoQ10, Placebo, HB-HIIT - End Stage Renal Disease | Phase 3 | Recruiting | Vanderbilt University Medical Center | 156 | 2023-06-01 | 2026-01-02 |
| A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia Vatiquinone - Friedreich Ataxia | Phase 3 | Active not recruiting | PTC Therapeutics | 130 | 2022-12-08 | 2025-10-30 |
| A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve) MT1621 - Thymidine Kinase 2 Deficiency | Phase 3 | Withdrawn | Zogenix MDS, Inc. | 2022-09-30 | 2023-09-01 | |
| A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease Vatiquinone - Inherited Mitochondrial Disease | Phase 3 | Completed | PTC Therapeutics | 101 | 2022-06-22 | 2025-12-22 |
| Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD) Elamipretide, Placebo - Mitochondrial Myopathies, Mitochondrial Pathology | Phase 3 | Completed | Stealth BioTherapeutics Inc. | 102 | 2022-04-29 | 2025-10-24 |
| Idebenone for the Preventive Treatment of Migraine Placebo, 90mg Idebenone, 270mg Idebenone - Migraine Disorders, Headache Disorders | Phase 3 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 180 | 2021-12-08 | 2025-05-15 |
| Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic Neuropathy NR082 injection, Sham Injection - Leber's Hereditary Optic Neuropathy (LHON) | Phase 2 / Phase 3 | Recruiting | Wuhan Neurophth Biotechnology Limited Company | 102 | 2021-06-18 | 2022-11-14 |
| A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia Vatiquinone, Placebo - Friedreich Ataxia | Phase 2 / Phase 3 | Completed | PTC Therapeutics | 146 | 2020-12-17 | 2026-04-13 |
| A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy Vatiquinone, Placebo - Mitochondrial Diseases, Drug Resistant Epilepsy | Phase 2 / Phase 3 | Terminated | PTC Therapeutics | 68 | 2020-09-28 | 2026-03-31 |
| Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency: Dichloroacetate (DCA), Placebo, Genotype - Pyruvate Dehydrogenase Complex Deficiency | Phase 3 | Active not recruiting | Saol Therapeutics Inc | 34 | 2020-07-14 | 2025-05-04 |
| A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia RT001, Placebo - Friedreich's Ataxia | Phase 3 | Completed | Biojiva LLC | 65 | 2019-10-30 | 2022-05-27 |
| A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) sepofarsen, Sham - Leber Congenital Amaurosis 10, Blindness | Phase 2 / Phase 3 | Active not recruiting | ProQR Therapeutics | 36 | 2019-04-04 | 2022-03-17 |
Showing 20 of 46. Sign in to see all of them.
Friedreich Ataxia (16) · Optic Atrophy, Hereditary, Leber (11) · Eye Diseases (6) · Eye Diseases, Hereditary (6) · Multiple Acyl Coenzyme A Dehydrogenase Deficiency (5) · Cytomegalovirus Infections (4) · HIV Infections (4) · Acquired Immunodeficiency Syndrome (3) · Cytomegalovirus Retinitis (3) · Genetic Diseases, Inborn (3) · MELAS Syndrome (3) · Nervous System Diseases (3) · Neurodegenerative Diseases (3) · Retinitis (3)
Metabolic Diseases (46) · Nutritional and Metabolic Diseases (46) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (37) · Genetic Diseases, Inborn (34) · Nervous System Diseases (33) · Heredodegenerative Disorders, Nervous System (29) · Neurodegenerative Diseases (25) · Brain Diseases (22) · Central Nervous System Diseases (22) · Cerebellar Diseases (16) · Spinal Cord Diseases (16) · Spinocerebellar Degenerations (16) · Cranial Nerve Diseases (12) · Optic Atrophy (11)
idebenone (6) · alpha-tocotrienol quinone (5) · Ganciclovir (4) · interferon gamma-1b (3) · salicylhydroxamic acid (3) · Valganciclovir (2) · Allopurinol (1) · Creatine (1) · Curcumin (1) · Deoxycytidine (1) · Dichloroacetic Acid (1) · Exercise (1) · Genotype (1) · Glucose (1) · Magnesium Oxide (1)
PTC Therapeutics (5) · Santhera Pharmaceuticals (5) · GenSight Biologics (4) · Amgen (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Wuhan Neurophth Biotechnology Limited Company (2) · Assistance Publique - Hôpitaux de Paris (1) · Biogen (1) · Biojiva LLC (1) · Hospices Civils de Lyon (1) · Huazhong University of Science and Technology (1) · Kenneth Myers, MD (1) · Khondrion BV (1) · Laboratoires Thea (1) · Larimar Therapeutics, Inc. (1)
United States (31) · France (16) · Germany (13) · Italy (13) · United Kingdom (13) · Canada (10) · Spain (10) · Netherlands (7) · Australia (6) · Brazil (6) · Belgium (5) · Austria (4) · China (4) · New Zealand (4) · Denmark (2)
David Lynch, MD (2) · Nancy Newman, MD (2) · Susan Perlman, MD (2) · Vinay Penematsa, MD (2) · Adolfo D. Rodriguez-Carrizalez, PhD (1) · Annette S. Feigenbaum, MD (1) · Baback Roshanravan, MD/MPH (1) · Beatrice A Golomb, MD, PhD (1) · Bin Li, MD (1) · Bin Li, PhD,MD (1) · David A. Wohl, MD (1) · Diana Rosas, MD, MS (1) · Douglas S. Kerr, MD, PhD (1) · Feinberg J (1)
PMID 36449262, PMID 34108929, PMID 21779958, PMID 11972582, PMID 1463007, PMID 1674640, PMID 18441370, PMID 18441371, PMID 18774912, PMID 1928099, PMID 19632953, PMID 20065258, PMID 20697044, PMID 21392622, PMID 21586650, PMID 21788663, PMID 22612072, PMID 22644094, PMID 23063736, PMID 24396955, PMID 25916335, PMID 25950380, PMID 26321318, PMID 26606867, PMID 26892229, PMID 27386292, PMID 27426279, PMID 27749593, PMID 28132202, PMID 28701493, PMID 29298622, PMID 30103342, PMID 31237206, PMID 31495483, PMID 3201231, PMID 33451738, PMID 35747889, PMID 39699886, PMID 5063796
2015 (2), 2017 (2), 2025 (2), 2018 (1), U01AT000613 (1)